Casgevy; Overview On December 8, 2023, the U.S. Food and Drug Administration (FDA) approved two groundbreaking gene therapies, Casgevy and Lyfgenia, for the treatment of … Continue reading Casgevy – CRISPR-Based Therapy for Sickle Cell Disease